Blueprint Medicines Corporation – Filings and Transcripts – BamSEC

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

SEC EDGAR

Financials Filter

ended 03/31/25 Q1

ended 12/31/24 FY 2024

ended 09/30/24 Q3

ended 06/30/24 Q2

ended 03/31/24 Q1

Prospectuses and Registrations Filter

Securities registration termination

Removal from listing

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Ownership Filter

Pentwater Capital Management LP

Avoro Capital Advisors LLC

Price T Rowe Associates Inc

Landsittel Michael

News Filter

Contingent Value Rights Agreement

Shareholder Vote Results

Adds Fast-Growing and Only Approved Medicine for Advanced and Indolent Systemic Mastocytosis to the Sanofi Portfolio

Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (Avapritinib) Full Year Revenue Guidance

Reports Fourth Quarter and Full Year 2024 Results

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Other Filter

Notice of effectiveness

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission – amended

Scanned paper annual report submission